Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Mozes

Clinical Cardiac Electrophysiology Boise, ID Medical Doctor

NPI 1679733414 CMS profile 1291371

287 W Jefferson St, Ste 230, Boise, ID 83702

Open in the dashboard

General payments

$26,010

318 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$18,301 paid to institutions, not to them · program year 2020

Through program year 2025, Joshua Mozes of Boise, ID is reported in the CMS Open Payments database as having received $26,010 across 318 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $18,301 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 58th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $670 31
2024 General $2,592 40
2023 General $2,221 79
2022 General $2,734 71
2021 General $665 33
2020 General $9,622 39
2019 General $7,506 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Mozes
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Joshua Mozes were reported at $670. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Joshua Mozes Clinical Cardiac Electrophysiology median Middle half National median
2019 $7,506 $2,361 $585–$8,260 $163
2020 $9,622 $993 $247–$4,351 $114
2021 $665 $1,185 $326–$4,739 $132
2022 $2,734 $2,073 $554–$6,789 $149
2023 $2,221 $2,568 $759–$8,159 $160
2024 $2,592 $2,557 $703–$7,403 $164
2025 $670 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $20,547 100 payments
  2. Boston Scientific Corporation $3,473 148 payments
  3. Impulse Dynamics (USA) Inc. $514 7 payments
  4. Medtronic, Inc. $260 13 payments
  5. Pfizer Inc. $204 11 payments
  6. Novartis Pharmaceuticals Corporation $166 8 payments
  7. Siemens Medical Solutions USA, Inc. $147 1 payment
  8. E.R. Squibb & Sons, L.L.C. $139 8 payments
  9. Philips Electronics North America Corporation $88 1 payment
  10. Kiniksa Pharmaceuticals International, plc $63 2 payments
  11. Other $410 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $16,038 35 payments
  2. Food and Beverage $7,577 269 payments
  3. Travel and Lodging $2,131 11 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $250 1 payment
  5. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. Ensite Cardiac Mapping System $16,038 35 payments
  2. AMPLATZER AMULET $1,936 22 payments
  3. AVEIR $1,378 9 payments
  4. WATCHMAN Access System $1,197 60 payments
  5. OPTIMIZER Cardiovascular Device $514 7 payments
  6. OPTIMIZER Cardiovascular Device $514 7 payments
  7. WATCHMAN Pain Management $360 19 payments
  8. General Therapies $287 3 payments
  9. EMBLEM $273 2 payments
  10. WATCHMAN Structural Heart $227 14 payments
  11. Other $3,709 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,088

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$321,371

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

37.7%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 198 $251,468
Xarelto Rivaroxaban Brand 23 $29,009
Multaq Dronedarone Hcl Brand 14 $27,978
Flecainide Acetate Generic 61 $3,157
Sotalol Sotalol Hcl Brand 99 $1,927
Metoprolol Succinate Generic 119 $1,491
Diltiazem 24hr Er Diltiazem Hcl Brand 36 $1,394
Colchicine Generic 74 $980
Amiodarone Hcl Generic 24 $882
Pantoprazole Sodium Generic 81 $541

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$205,723

Medicare's payments for the services billed

Medicare patients

474

Average age 76

Services billed

3,180

210 women, 264 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 70%
Arthritis 46%
Ischemic heart disease 39%
Heart failure 38%
Chronic kidney disease 27%
Diabetes 20%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $63
$63 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $43
$43 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $43
$43 — —
VYNDAQEL
  • PFIZER INC. $30
$30 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $17
$17 198 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record